Dynavax Technologies Corporation · Berkeley, CA United States ·(NASDAQ (CM): DVAX)

Dynavax Technologies is trying to reprogram the way the body reacts to disease. The firm focuses on immunostimulatory sequences (ISS), short strands of DNA found to strengthen the immune system. The company's lead candidate in clinical trials is HEPLISAV, a hepatitis B vaccine. Dynavax is working on other candidates that might lead to treatments for asthma, colorectal cancer, and hepatitis C. Dynavax has partnered with AstraZeneca to research preclinical work on a treatment for asthma and chronic obstructive pulmonary disease, while Symphony Dynamo has poured in money to fund the company's colorectal cancer and hepatitis C research. To read the full description, subscribe now.